Aduro Biotech Inc.

The Johns Hopkins University

Dna Plant Technology Corporation

William G Hanson

Peter M Lauer

Dirk G Brockstedt

Justin Skoble

Meredith Lai Ling Leong

Marcella Fasso

Thomas W Dubensky, Jr

Neal I Gutterson

Charles George Drake

Christopher Steven Rae

William Stanford Luckett, Jr

Dirk Brockstedt

Thomas Dubensky

The present invention provides nucleic acid and protein sequences that enhance the expression of fusion proteins by host cells, and in particular bacterial species, together with methods use thereof. While described hereinafter in terms of expression of fusion proteins by, the present invention is applicable to expression of fusion proteins generally.

Protein expression enhancer sequences and use thereof

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to fusion proteins comprising an epidermal growth factor receptor variant III (EGFRvIII) polypeptide and a mesothelin polypeptide, and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins. In some embodiments, the nucleic acid molecules can encode an EGFRvIII-mesothelin fusion protein comprising an amino acid sequence that is at least i) 90% identical, ii) 95% identical, or iii) 99% identical to EGFRvIIIx5-mesothelinas set forth in SEQ ID NO:8.

Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.

Immunogenic fusion proteins for the treatment of cancer

The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.

Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

The present invention provides facultatively attenuated bacterial species and methods of preparation and use thereof. The term 'facultatively attenuated' as used herein refers to a bacterium which comprises a set of defined recombinant modifications which have substantially no effect on the ability of the bacterium to grow by multiplication when the bacterium is outside of its host organism, but which result in deletion of one or more genes essential for multiplication of the bacterium when the bacterium is introduced into its host organism, for example within host cells of a vaccinate recipient. These recombinant modifications take advantage of regulatory sequences which preferentially induce expression of genes within the mammalian host.

Facultatively attenuated bacterial species and methods of preparation and use thereof

The present invention provides methods for eliminating plants containing non-T-DNA sequences derived from a T-DNA vector. More specifically, the present invention provides a method for killing plant cells that receive non-T-DNA sequences based on incorporation of a lethal polynucleotide sequence into the non-T-DNA portion of the vector.

Growing community of inventors

Walnut Creek, CA, United States of America

William G Hanson